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Abstract When grown under hypothermic 
conditions, Chinese Hamster Ovary (CHO) cells 
become growth arrested in the G0/G1 phase of the cell 
cycle and also often exhibit increased recombinant 
protein production.    In this study, we have validated 
this hypothesis by stimulating hypothermic growth 
using basic fibroblast growth factor and fetal bovine 
serum supplementation.  This method led to 7.7- and 
4.9-fold increase in total production compared to the 
37 oC and 32 oC control cultures, respectively.  This 
proof-of-concept study will motivate the creation of 
cell lines capable of growing at low temperatures for 
use in industrial processes. 
 
Key words: hypothermic growth, CHO cell, 
Interferon gamma, specific productivity 
 
I. INTRODUCTION 
 
Recombinant human glycoproteins produced by 
Chinese Hamster Ovary (CHO) cells are an important 
class of therapeutic molecules and investigating 
means of improving the production rate of these 
glycoproteins is therefore of great interest.  Culturing 
CHO cells under mild hypothermia (30-33 oC) leads 
to growth arrest in the G0/G1 phase of the cell cycle 
[1] and, in some cases, cause an increase in specific 
productivity of recombinant protein [2-7].  
Controlled proliferation, achieved by inducing 
growth arrest in the G0/G1 phase by chemical, 
environmental or genetic means, is often used to 
increase CHO specific productivity and thus it is 
commonly assumed that enhanced hypothermic 
productivity is due to growth arrest [1].  However, we 
have shown previously that the positive effect of 
hypothermia on recombinant protein production is 
not due to G0/G1 growth arrest but rather is due to  
 
 
elevated recombinant mRNA levels [8].  At both 32 
oC and 37 oC, specific productivity was growth- 
associated, increasing as the percentage of cells in the 
S phase increased, demonstrating that a cell line can 
be both a growth-associated producer and have 
enhanced productivity under hypothermic conditions.  
In other words, hypothermia enhanced productivity 
whereas growth arrest diminished productivity for the 
recombinant CHO line used in the study.   
Based on these findings, it was hypothesized that 
the best conditions for maximizing total recombinant 
protein production would be cells capable of actively 
growing at low temperature, as these cultures would 
maintain the benefits of hypothermia on specific 
productivity whilst also achieving the high cell 
densities characteristic of active growth, and 
consequently total production would be enhanced.     
The goal of this study was to test this hypothesis by 
achieving “active” hypothermic growth, an easily 
achievable culture condition in industrial processes. 
 Hypothermia is known to lead to growth arrest at 
least in part by causing increased expression of cell 
cycle regulatory proteins.  When mammalian cells 
are exposed to cold shock, p53 protein levels increase 
significantly, followed by an increase in p21 mRNA 
and then p21 protein [9].  The level of p53 mRNA is 
unchanged during this sequence of events, indicating 
that low temperature exerts a post-transcriptional, 
stabilizing effect on p53 [9].  The mechanism by 
which cold shock stabilizes p53 remains unknown 
[9]. For the current study, we hypothesized that in 
order to stimulate cells to grow at low temperature, 
various growth factors could be used, providing 
positive growth signals to counteract the negative 
effects of hypothermia on the cell cycle engine.  
Specifically, we used basic fibroblast growth factor 
(bFGF) and insulin on adherent cultures and fetal 
bovine serum (FBS) on suspension cultures, in order 
to stimulate hypothermic growth.  These particular 
mitogens have previously been shown to have 
positive effects on CHO proliferation [10-14]. 
 
II. MATERIALS AND METHODS 
 
A. Cell Line and Medium 
   
  A CHO cell line expressing human IFN-γ (CHO-γ) 
driven by the SV40 early promoter was obtained 
from Dr. Walter Fiers [15].  This recombinant cell 
line was created by cotransfection of dihydrofolate 
reductase (DHFR) and IFN-γ genes into a DHFR 
deficient CHO cell line.  The basal medium used for 
adherent cell culture was Dulbecco’s Modified Eagle 
Medium (DMEM) (Invitrogen, Grand Island, NY) 
supplemented with 10% FBS (HyClone, Logan, UT), 
20 U ml-1 penicillin-20 µg ml-1 streptomycin mix 
(Invitrogen), and 0.25 µM methotrexate.  The basal 
medium used for suspension culture was HyQ PF-
CHO (HyClone) containing 20 mM glucose and 
supplemented with 4 mM glutamine, 0.1% Pluronic 
F-68 (Invitrogen), 20 U ml-1 penicillin-20 µg ml-1 
streptomycin mix (Invitrogen) and 0.25 µM 
methotrexate.  Reagents were from Sigma Chemical 
Company (Saint Louis, MO) unless noted otherwise. 
 
B. Adherent Cell Culture 
   
  Following 2-4 passages of stock cells, mid 
exponential cells with viability greater than 95% 
were centrifuged at 950 rpm for 5-10 minutes and 
resuspended in fresh medium.  One quarter million 
cells were resuspended in 3 ml of medium and added 
to each well of a group of 6-well plates.  Cells were 
incubated at 32 oC, or 37 oC in humidified incubators 
with 7.5% CO2 overlay.  A temperature of 32 oC was 
used because this temperature has been shown 
previously to increase CHO-γ specific productivity 
[7].  However, 32 oC is not necessarily the optimal 
temperature for hypothermic culture.  Every day, 2 
wells per condition were sacrificed for cell counting.  
The experiments were terminated once the percent 
viability was less than 80%. 
  Various amounts of stock growth factor solutions 
were added to the medium at the beginning of the 
experiments.  In all cases, the growth factors were 
dissolved in the standard basal medium containing 
the same supplements as the control cultures.  Thus, 
all conditions were identical except for the presence 
or absence of growth factors.  The insulin stock 
solution contained 100 µg ml-1 insulin and the bFGF 
stock solution contained 25 µg ml-1 bFGF.  Insulin 
concentrations of 5, 15 and 25 µg ml-1, bFGF 
concentrations of 13, 21, 42 and 45 ng ml-1, and a 
mixed culture containing 15 µg ml-1 insulin and 21 ng 
ml-1 bFGF were tested. 
 
C. Suspension Cell Culture 
 
  Following 2-4 passages of stock cells, mid 
exponential cells with viability greater than 95% 
were centrifuged at 950 rpm for 5-10 minutes and 
resuspended in fresh medium at a density of 2.5x105 
viable cells ml-1.  The experiments were conducted in 
250-ml Erlenmeyer flasks with a starting volume of 
50 ml.  Cells were incubated at 32 oC, or 37 oC on 
shaker platforms set at 100 rpm in humidified 
incubators with 7.5% CO2 overlay.  All cell culture 
experiments were conducted in duplicate.  Samples 
were taken at least daily for cell counting and 
viability determination.  The experiments were 
terminated once the percent viability was less than 
80%. 
  For cultures aimed at achieving active hypothermic 
growth, the procedure was the same as outlined 
above except that 10 or 25% FBS was added to the 
initial culture.  Volume was maintained the same as 
the other cultures (50 ml) by adding less medium to 
the FBS-containing cultures. 
 
D. Cell Enumeration and Viability 
 
  The procedure used for counting adherent cell 
cultures was designed to ensure that both the 
adherent cells and any dead or viable cells that had 
become detached during the course of the experiment 
were included in the total cell count.  Medium was 
removed from the cells and centrifuged at 950 rpm 
for 5 minutes to retain detached cells for counting.  
After centrifugation, the supernatant was removed 
and stored at -80 oC for future analyses.  The 
adherent cells were treated with a 0.05% Trypsin / 
EDTA solution (Invitrogen) for 5-10 minutes at 37 
oC.  The trypsin was removed and the cells were 
pooled with the previously centrifuged, detached 
cells.  The well was rinsed with fresh medium to 
remove any remaining cells and the rinse solution 
was combined with the trypsin pool.  The cell 
number per well was then determined by counting the 
cells using a hemacytometer and multiplying the 
concentration by the known volume of the cell 
solution.  Each sample was counted in duplicate and 
each count consisted of at least 200 total cells.  If the 
results of the duplicate counts did not agree within 
10% of each other, additional counts were conducted.  
The cell viability was determined using the trypan 
blue exclusion assay in conjunction with cell 
counting. 
  Approximately 0.5 – 1 ml samples were removed 
from well-mixed suspension cultures.  The cell 
concentration was determined by counting the cells 
using a hemacytometer.  Each sample was counted in 
duplicate and each count consisted of at least 200 
total cells.  If the results of the duplicate counts did 
not agree within 10% of each other, additional counts 
were conducted.  The cell viability was determined 
using the trypan blue exclusion assay in conjunction 
with the cell counting. After counting, samples were 
centrifuged at 950 rpm for 5 minutes and the 
supernatant was removed from the cell pellet and 
stored at -80 oC for future analyses. 
 
E. IFN-γ Concentration 
 
  IFN-γ concentration was measured using an ELISA 
kit (HyCult biotechnology b.v., Uden, the 
Netherlands).  To reduce the uncertainty of ELISA 
measurements, samples were measured in triplicate. 
 
F. Cell Cycle Analysis 
 
  At least one million cells per sample were collected 
by centrifugation for 5 minutes at 950 rpm and 
washed once with 5 ml of PBS. After a second 
centrifugation step, cells were resuspended in 0.5 ml 
PBS, followed by addition of 4.5 ml of ice-cold 70% 
ethanol and stored at –20 oC for 1-4 weeks.  The cells 
were centrifuged and the ethanol was aspirated. Then, 
the cells were resuspended in 5 ml PBS, held at room 
temperature for 60 seconds and centrifuged again.   
Finally, the cells were resuspended in 1 ml of the 
propidium iodide (PI)/Triton X-100 staining solution 
[0.1% (v/v) Triton X-100; 10 µg ml-1 PI; and 0.2 mg 
ml-1 RNase A in PBS] and incubated at room 
temperature for 30 minutes prior to the flow 
cytometry analysis.  The flow cytometry 
measurements were carried out on EPICS® Elite flow 
cytometer (Coulter Corporation, Miami, FL) 
equipped with a single argon ion laser with the 
excitation wavelength at 488 nm and emission set at 
610 nm. DNA distribution histograms were analyzed 
with the WinMDI Multi-Cycler 2.7 software 
 
III. RESULTS 
 
A.Insulin and bFGF stimulate CHO growth at low 
temperature 
 
  Given that hypothermia serves as a negative growth 
signal, it was hypothesized that hypothermic active 
growth could be achieved by providing high 
concentrations of growth factors to serve as positive 
growth signals, thereby overcoming the hypothermic 
arrest.  To test the feasibility of this approach, the 
effect of different concentrations of the growth 
factors insulin and bFGF on cell density was 
determined.  The concentrations tested were similar 
to those shown by other researchers to have a positive 
effect on CHO cells [5 µg ml-1 insulin [13] and 20 ng 
ml-1 bFGF [10].  Figure 1 shows the peak cell density 
obtained at 32 oC for the different growth factor 
conditions tested.  Clearly, both insulin and bFGF 
treatment cause higher cell densities relative to the 
control and some level of hypothermic active growth 
is therefore achieved. 
 
 
Figure 1: Effect of Growth Factors on Peak Cell 
Density: Adherence Cells 
 
  The combination of insulin and bFGF gave a 
slightly higher cell density than either of the two 
growth factors alone, but the additive effect was not  
significant.  The viability for the cultures containing 
insulin was consistently lower than the bFGF 
cultures.  Insulin has previously been observed to 
cause cells growth-arrested by serum withdrawal to 
proliferate but also to undergo apoptosis [13] and it is 
likely that a similar event is taking place here, 
resulting in lower cell viability.  Because of this 
detrimental effect and the fact that insulin did not 
give higher cell density than bFGF and therefore only 
bFGF was tested in the subsequent experiments. 
 
B.  bFGF supplementation leads to a higher fraction 
of S phase cells during hypothermic culture 
 
  The cell growth curves of control and bFGF-treated 
cultures at 32 oC and 37 oC are shown in Figure 2.  
The growth factor causes the peak cell density to 
decrease slightly at 37 oC whereas it causes a 
significant increase in cell density at 32 oC, with peak 
cell density doubling relative to the untreated control. 
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Figure 2: bFGF Stimulation of Cell Growth 
  
  The effect of bFGF at 32 oC is evident at the cell 
cycle level, as shown in Figure 3, which shows the 
percentage of S phase cells versus time.  As early as 
day 2, the bFGF-treated hypothermic culture has a 
significantly higher percent of cells in S phase, and 
this trend continues for the remainder of the culture. 
 
Figure 3: bFGF On Percent of S Phase Cells 
 
C. Hypothermic active growth increases the total 
IFN-γ  production 
 
  At the end of the cultivation, the IFN-γ 
concentrations were determined and it can be seen 
that the IFN-γ is significantly higher for the bFGF-
treated, hypothermic culture (Figure 4) compared to 
any of the other three conditions.  The total IFN-γ 
production was 110% compared to the 37 oC control 
and by 50% compared to the 32 oC control.  Thus, 
this culture concept, active hypothermic growth via 
growth factor addition, is validated as a means for 
improving total production of recombinant 
glycoproteins. 
 
 
Figure 4: Active Hypothermic Growth Effect on 
Total IFN-γ Production 
 
  The bFGF itself appears to have a negative effect on 
specific productivity, as can be seen by the 20-25% 
decrease relative to the non-treated control (Figure 
5), regardless of culture temperature.  The molecular 
mechanism for this detrimental effect is unknown.  
However, the critical point for validating active 
hypothermic growth is that the ratio of 32 oC to 37 oC 
specific productivity remains essentially unchanged 
for the non-treated and bFGF-treated samples (Figure 
6) showing that the positive effect of hypothermia on 
specific productivity can be achieved simultaneously 
with active growth. 
 
 
Figure 5: bFGF Reducing Average Specific 
Productivity at Different Temperatures 
 
 
Figure 6: Positive Effect of Hypothermic Growth  
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D. Hypothermic active growth in suspension culture 
 
  For an industrial production process, cells are 
usually grown in suspension culture.  To verify that 
hypothermic active growth is also feasible in 
suspension culture, suspension cultures were 
subjected to mitogen stimulation using high doses of 
FBS.  The basal medium used was a commercially 
available protein-free medium.  The effect of 0, 10 
and 25% (v/v) FBS on cell growth at 37 oC and 32 oC 
is shown in Figure 7.  Clearly, hypothermic active 
growth is feasible in suspension culture, as seen from 
the data.  In fact, the hypothermic growth is far more 
impressive than what had been obtained for the 
bFGF-stimulated adherent cells, with hypothermic 
culture in the presence of FBS reaching the same 
peak density as 37 oC control. 
 
E.  Hypothermic active growth greatly enhances total 
IFN-γ production in suspension culture 
 
As hypothesized, the hypothermic active growth 
cultures were able to simultaneously maintain high 
productivity and achieve high cell density.  The 
combined factors yielded a significant enhancement 
in the total IFN-γ production (Figure 8).  The 25% 
FBS culture at low temperature had 7.7-fold higher 
total production than the 37 oC control and 4.9-fold 
higher than the 32 oC control.  The FBS had an 
insignificant effect on 37 oC total production, and 
thus the enhancements under hypothermic conditions 
can be attributed directly to the improved growth 
rather than to a secondary effect of the FBS on 
productivity. 
 
F. Hypothermic active growth greatly enhances total  
IFN-γ production in suspension culture 
 
  As hypothesized, the hypothermic active growth 
cultures were able to simultaneously maintain high 
productivity and achieve high cell density.  The 
combined factors yielded a significant enhancement 
in the total IFN-γ production (Figure 8).  The 25% 
FBS culture at low temperature had 7.7-fold higher 
total production than the 37 oC control and 4.9-fold 
higher than the 32 oC control.  The FBS had an 
insignificant effect on 37 oC total production, and 
thus the enhancements under hypothermic conditions 
can be attributed directly to the improved growth 
rather than to a secondary effect of the FBS on 
productivity. 
 
Figure 7: Serum Supplementation on Cell Densities 
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Figure 8: Serum Supplementation on IFN-γ 
Production 
 
IV. CONCLUSIONS AND DISCUSSION 
 
It was hypothesized that cells capable of 
maintaining active growth at low temperature would 
prove to be the optimal production platform for 
maximizing IFN-γ production.  This is mainly 
attributed to the fact that CHO-γ was a growth-
associated producer that also had enhanced 
productivity at low temperature [8].  The hypothesis 
was proven to be correct by stimulating hypothermic 
growth using mitogens.  The growth factors 
maintained the cells in its cell division cycles instead 
of arresting in G0/G1, resulting in much higher cell 
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densities at low temperature without sacrificing the 
enhanced specific productivity.  This, consequently, 
resulted in higher IFN-γ concentrations. 
The greatly improved cell densities are due 
somewhat to improved growth rates but are also due 
to exponential growth being maintained for a longer 
period of time.    The growth rate was improved by 
about 10-35% at the low temperature.  More 
importantly, the mitogen-stimulated cells maintained 
exponential growth for about 2 days longer than the 
control for all the hypothermic conditions tested.  As 
a result, the integrated viable cell densities (IVCD) of 
the active hypothermic growth cultures were 
comparable to, or greater than, the 37 oC controls. 
The molecular mechanism by which the mitogens 
maintain the cells in active growth is likely by 
exerting a positive effect on cell cycle progression.  
Growth factors, such as bFGF, bind specific cell 
surface receptors.  This binding event in turn 
increases the kinase activity of the receptor, which 
then leads to a cascade of signals promoting growth 
[16].  It is known that hypothermia serves as a 
negative signal to the cell cycle control system, for 
example activating p53 and thereby triggering a 
further cascade that ultimately prevents the cyclin-
dependent kinase (CDK) molecules from activating 
cell passage to the S phase [9].  Growth factors, on 
the other hand, will have the opposite effect, 
promoting CDK activity or inhibiting cyclin-
dependent kinase inhibitors (CKI) as a result of their 
initial binding and activation of the cell surface 
receptors and thereby stimulating cells to progress 
into the S phase.  Thus, there appears to be a “tug-of-
war” effect on the cell cycle, with hypothermia 
promoting arrest and mitogens promoting growth and 
the outcome depending on mitogen level.  For 
example, increasing the bFGF concentration has a 
positive effect on improving the peak cell density 
achievable in a batch culture (Figure 1).  Whether 
this trend would continue beyond the 45 ng ml-1 
bFGF concentration tested is unknown.  Insulin, on 
the other hand, did not have such an effect, with 5-25 
mg ml-1 causing essentially the same peak density.  In 
this case, this may be due to the previously 
mentioned increasing levels of apoptosis with 
increasing levels of insulin, and thus the positive 
effect on hypothermic growth being masked by the 
cell death. 
The hypothermic growth-promoting effect of FBS 
in suspension culture was more impressive than the 
effect of bFGF in adherent culture.  Whereas bFGF 
treatment at 32 oC caused cells to reach 44% and 67% 
of 37 oC growth rate and peak density, respectively, 
FBS treatment at 32 oC allowed cells to reach 80% 
and 103% of the 37 oC values of these two 
parameters.  The end result was a spectacular, multi-
fold increase in total IFN-γ production (Figure 8).  
Unfortunately, FBS cannot be used for new 
bioprocesses producing human therapeutics.  
Nevertheless, these results should motivate the search 
for a well-defined, FDA-approved growth factor or 
chemical formulation capable of achieving the level 
of hypothermic growth in suspension culture caused 
by FBS.  The effect of FBS on promoting 
hypothermic growth in adherent cultures was not 
tested here, because the CHO-γ cell line is FBS-
dependent when grown in adherent culture using 
DMEM medium, and thus a serum-free control was 
not practical. 
One of the major drawbacks of controlled 
proliferation strategies in general, including 
hypothermic culture, is that although specific 
productivity is higher, total production is not always 
significantly improved, due to the detrimental effect 
on cell density caused by controlled proliferation.  
This is evident in the hypothermic culture literature.  
For example, Furukawa and Ohsuye [2] found that 
specific productivity was highest at 32 oC, within the 
range 30 – 37 oC, for their recombinant CHO cell 
line.  However, culturing at 35 oC maximized total 
production, because this temperature achieved the 
optimum in the trade-off between higher productivity 
at low temperature and higher growth rates at 
elevated temperatures.  This was despite the fact that 
32 oC had a 50% higher specific productivity than 35 
oC.  A similar finding can be found in another 
hypothermic study, wherein specific productivity at 
30 oC was 40% higher than that at 33 oC, yet total 
production at the slightly higher temperature was 3 
times higher than at 30 oC [6].  By promoting active 
growth at low temperature, one no longer needs to 
compromise as significantly on the reduced growth 
rate and can operate closer to the temperature that 
gives highest specific productivity.  From the 
findings in this study, it is predicted that the above 
mentioned researchers would achieve maximum total 
production by stimulating growth at the lower 
temperatures, thereby achieving the high cell density 
whilst simultaneously maintaining the high specific 
productivity. 
Adding growth factors to medium to obtain active 
hypothermic growth may not be cost effective in an 
industrial process.  It may be far more practical to 
produce cell lines capable of growing under 
hypothermic conditions, while maintaining increased 
specific productivity.  We are currently in the process 
of isolating such CHO cells, which would result in a 
far more cost effective means of achieving active 
hypothermic growth. 
The general concept shown here, namely 
promoting growth under otherwise unfavorable 
conditions, may also be applicable and beneficial to 
other controlled proliferation methods.  For example, 
it may be useful to promote active growth in the 
presence of sodium butyrate, the enhanced specific 
productivity of which does not appear to depend on 
growth arrest [8]. 
In conclusion, this study introduced and validated 
a novel cell culture strategy, namely active 
hypothermic growth.  This finding is envisioned to be 
applicable to any cell line that has growth-associated 
productivity and also has enhanced productivity 
under hypothermic conditions.  The finding also 
applies to suspension culture and therefore is relevant 
for improving production in industrial processes. 
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